







PROGRAMME

Chairpersons:

Dr Stewart Geary (Eisai)
Dr Kyoko Imamura (The University of Tokyo)

21:00-21:05	Welcome message from <i>Dr Kazuya Iwamoto</i> ,
	Drasidant of IADhMad

21:05-21:15 Brief overview of COVID-19 pandemic in Japan *Prof Kotone Matsuyama*, Department of Health Policy

and Management, Nippon Medical School

21:15-21:35 Current situation and challenges in COVID-19

treatments and vaccines development

Dr Atsushi Tsukamoto, Vice President, New Drug

Regulatory Affairs, Daiichi Sankyo

21:35-21:55 Sustainable ethical review and quality assurance in

R&D operations in times of COVID-19

Mr Naoki Tsutsumi, Graduate School of Pharmaceutical

Sciences, The University of Tokyo

21:55-22:25 Panel discussion

22:25-22:30 Closing message by Dr Marco Romano,

IFAPP President



Time Schedule

07:00 - 08:30 AM EST

12:00 - 13:30 PM GMT

01:00 - 02:30 PM CET

21:00 - 22:30 PM JST





LEARNING OUTCOMES

Expected learning outcomes:

- Understand the epidemiological situation of the COVID-19 infection in Japan
- Understand the current situation and challenges of the vaccines and antivirals development to manage COVID-19
- Describe the use of online IRB meetings and remote audits for clinical trials in Japan
- Discuss future treatment opportunities and clinical trial management under the COVID-19 pandemic

Registration

- This webinar is free to everybody.
- Click here for registration.

Organized by: IFAPP, IFAPP Academy and JAPhMed

Sponsor: DIA Japan

Duration

The webinar will last about 90 minutes.





